Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

DEXCOM INC Director's Dealing 2025

Sep 4, 2025

30198_dirs_2025-09-04_69de13ca-aa87-4d41-9a03-352af685bc63.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: DEXCOM INC (DXCM)
CIK: 0001093557
Period of Report: 2025-09-02

Reporting Person: Sylvain Jereme M (EVP, Chief Financal Officer)

Non-Derivative Transactions

Date Security Code Shares Price A/D Holdings After Ownership
2025-09-02 Common Stock S 4824 $74.17 Disposed 118657 Direct

Footnotes

F1: On May 27, 2025, Mr. Sylvain adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Sylvain. The shares set forth above were sold pursuant to the 10b5-1 Plan.

F2: Included in this number are 83,328 unvested restricted stock units, 35,906 of which were granted on March 8, 2025 and shall vest through March 8, 2028, 22,798 of which were granted on March 8, 2025 and shall vest through March 8, 2027, 17,368 of which were granted on March 8, 2024 and shall vest through March 8, 2027, and 7,256 of which were granted on March 8, 2023 and shall vest through March 8, 2026.